Zocor vs. Praluent

See how Zocor and Praluent compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Zocor is a daily oral statin pill, while Praluent is an injectable PCSK9 inhibitor given every two or four weeks.

  • Praluent is typically added on top of statin therapy like Zocor when LDL remains too high, not used as a replacement for it.

  • Zocor has decades of use and low-cost generics, while Praluent is a newer biologic with no generic alternative and a much higher price.

Zocor vs. Praluent Drug Summary

Zocor

Zocor (simvastatin) is a statin that lowers LDL cholesterol by blocking a liver enzyme the body uses to make it. It is taken as a single oral tablet once a day, usually in the evening. It has been prescribed since 1991 and is now widely available as an inexpensive generic.

Praluent

Praluent (alirocumab) is a PCSK9 inhibitor, an injectable antibody that helps the liver clear more LDL cholesterol from the blood. It is self-injected under the skin every two weeks, or every four weeks at a higher dose. It is usually added to statin therapy when LDL is still too high.

Zocor vs. Praluent Side Effects

Zocor

Most common
upper respiratory infection (up to 9%)
headache (up to 7%)
abdominal pain (up to 7%)
constipation (up to 7%)

Praluent

Most common
nasopharyngitis (up to 11.3%)
injection site reactions (up to 7.2%)
influenza (up to 5.7%)
urinary tract infection (up to 4.8%)

Zocor vs. Praluent Dosage

Zocor

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily At the start
Maximum dose 80 mg once daily If needed
Dose changes 3 increases As tolerated

Praluent

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 75 mg every 2 weeks At the start
Maximum dose 300 mg every 4 weeks If needed
Dose changes 2 increases As tolerated

Zocor vs. Praluent Indications

Zocor

Zocor is FDA-approved to lower LDL cholesterol in adults with primary hyperlipidemia and to treat familial hypercholesterolemia, including in children 10 and older. It is also approved to reduce the risk of heart attack, stroke, and death in people with heart disease or diabetes at high cardiovascular risk.

  • Primary hyperlipidemia in adults

  • Heterozygous familial hypercholesterolemia (ages 10+)

  • Adjunct for homozygous familial hypercholesterolemia

  • Cardiovascular risk reduction in high-risk adults

Praluent

Praluent is FDA-approved to lower LDL cholesterol in adults with primary hyperlipidemia, usually added to diet and maximally tolerated statin therapy. It also treats heterozygous familial hypercholesterolemia in patients 8 and older and reduces the risk of heart attack, stroke, and hospitalization for unstable angina.

  • Primary hyperlipidemia, added to statin therapy

  • Heterozygous familial hypercholesterolemia (ages 8+)

  • Cardiovascular event risk reduction after heart disease

  • Not approved for homozygous familial hypercholesterolemia

Zocor vs. Praluent Pros and Cons

Zocor

Zocor is a well-established statin with decades of safety data and low-cost generic availability. As a pill taken once daily, it is simple to use, though it can interact with certain medications and carries a dose-related risk of muscle problems.

Pros

  • Inexpensive generic, roughly $75 to $100 per month

  • Taken as a simple oral tablet

  • Decades of real-world safety data since 1991

  • Approved as adjunct for homozygous familial hypercholesterolemia

Cons

  • Risk of myopathy and rhabdomyolysis, especially at 80 mg

  • Interacts with many drugs metabolized by CYP3A4

  • Contraindicated in pregnancy

  • Not approved for children under 10

Praluent

Praluent offers an option for patients who need more LDL lowering than a statin alone provides, using an antibody injection instead of a daily pill. It has strong outcomes data in patients with recent acute coronary syndrome, but it costs significantly more and has no generic alternative.

Pros

  • Effective add-on when statins alone aren't enough

  • Flexible dosing every 2 or 4 weeks

  • Approved for children as young as 8 with HeFH

  • Outcomes data from ODYSSEY OUTCOMES trial after acute coronary syndrome

Cons

  • Roughly $500 to $640 per month without insurance

  • Requires self-injection rather than a pill

  • No generic or biosimilar currently available

  • Not approved for homozygous familial hypercholesterolemia

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.